| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-12-2325 |
| P698 | PubMed publication ID | 23108136 |
| P50 | author | Eric Tartour | Q40874974 |
| Magali Terme | Q41596058 | ||
| Julien Taïeb | Q41784351 | ||
| P2093 | author name string | Simon Pernot | |
| Antoine F Carpentier | |||
| Nadine Benhamouda | |||
| Elie Marcheteau | |||
| Orianne Colussi | |||
| Olivier Dubreuil | |||
| Federico Sandoval | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 539-549 | |
| P577 | publication date | 2012-10-29 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer | |
| P478 | volume | 73 |
| Q64102469 | A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer |
| Q64245040 | A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma |
| Q35060617 | A molecular signature for the prediction of recurrence in colorectal cancer |
| Q38597921 | A murine-human chimeric IgG antibody against vascular endothelial growth factor receptor 2 inhibits angiogenesis in vitro |
| Q40929692 | A new strategy to target regulatory T cells in solid tumors |
| Q64988575 | Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients. |
| Q39359690 | Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial |
| Q47563356 | Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms. |
| Q46017879 | An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. |
| Q41596176 | Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade |
| Q57825996 | Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis |
| Q26747054 | Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents |
| Q38829551 | Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine |
| Q34523319 | Antiangiogenic therapy for glioblastoma: current status and future prospects |
| Q47111400 | Antiangiogenic therapy in breast cancer |
| Q93176289 | Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models |
| Q52763518 | Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade. |
| Q39203685 | Barriers to Radiation-Induced In Situ Tumor Vaccination. |
| Q35012765 | Bevacizumab plus ipilimumab in patients with metastatic melanoma |
| Q64080583 | Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets |
| Q91910781 | Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer |
| Q58781616 | Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu |
| Q36130505 | Cellular and molecular immunology of lung cancer: therapeutic implications. |
| Q38207980 | Chemotherapeutic targeting of cancer-induced immunosuppressive cells |
| Q35149637 | Classification of current anticancer immunotherapies |
| Q90273418 | Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series |
| Q37392642 | Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis |
| Q37697520 | Colorectal cancer and immunity: what we know and perspectives |
| Q28066199 | Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy |
| Q56892367 | Combination Immunotherapy in Non-small Cell Lung Cancer |
| Q64232953 | Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment |
| Q38447992 | Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? |
| Q92541892 | Contribution of Angiogenesis to Inflammation and Cancer |
| Q37683575 | Control of the adaptive immune response by tumor vasculature |
| Q27004733 | Control of the immune response by pro-angiogenic factors |
| Q52661758 | Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma. |
| Q26745516 | Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy |
| Q26773314 | Current status of immunotherapy |
| Q93081377 | Cutaneous Metastases in Ovarian Cancer |
| Q91657875 | Cutaneous Metastasis after Surgery, Injury, Lymphadenopathy, and Peritonitis: Possible Mechanisms |
| Q36976217 | Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. |
| Q92398759 | Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma |
| Q34614894 | Dysregulation in microRNA expression in peripheral blood mononuclear cells of sepsis patients is associated with immunopathology |
| Q41945623 | Effects of Feijining Decoction on vascular endothelial growth factor protein expression and changes of T cell subsets in Lewis lung carcinoma-bearing mice |
| Q97520390 | Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy |
| Q47845243 | Efficacy for lung metastasis induced by the allogeneic bEnd3 vaccine in mice |
| Q100739241 | Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria |
| Q45870426 | Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice. |
| Q93103180 | Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients |
| Q92479136 | Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors |
| Q89156992 | Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells |
| Q37195258 | Following up tumor-specific regulatory T cells in cancer patients |
| Q55262681 | Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. |
| Q47136084 | Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed? |
| Q43090164 | Home sweet home: the tumor microenvironment as a haven for regulatory T cells. |
| Q26853599 | Homeostasis and function of regulatory T cells (Tregs) in vivo: lessons from TCR-transgenic Tregs |
| Q64097077 | How to schedule VEGF and PD-1 inhibitors in combination cancer therapy? |
| Q28085029 | Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia |
| Q91584962 | Identification of key candidate genes for colorectal cancer by bioinformatics analysis |
| Q64898611 | Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location. |
| Q34458617 | Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. |
| Q35634179 | Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy |
| Q41401879 | Immune effects of bevacizumab: killing two birds with one stone |
| Q30275254 | Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma |
| Q48193633 | Immune recognition of irradiated cancer cells |
| Q39165919 | Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models |
| Q94452370 | Immunomodulation by anticancer cell cycle inhibitors |
| Q96954537 | Immunomodulation of NK Cells by Ionizing Radiation |
| Q28083450 | Immunosuppression associated with chronic inflammation in the tumor microenvironment |
| Q38413904 | Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some |
| Q36092885 | Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial |
| Q64121770 | Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancer |
| Q42549680 | Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning |
| Q50055217 | Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa |
| Q39479166 | Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients |
| Q26781098 | Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data |
| Q92684124 | Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer |
| Q34926323 | Inhibition of the differentiation of monocyte-derived dendritic cells by human gingival fibroblasts |
| Q92857735 | Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer? |
| Q64251353 | LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer |
| Q61805290 | Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date |
| Q38806922 | Leveraging the immune system to treat advanced thyroid cancers |
| Q91792673 | LncRNA, a novel target biomolecule, is involved in the progression of colorectal cancer |
| Q89823508 | Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment |
| Q38181691 | Lung cancer: potential targets for immunotherapy |
| Q33760560 | Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: A case report |
| Q35753931 | Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine |
| Q58791422 | Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis |
| Q49981856 | Microarray analysis reveals Tmub1 as a cell cycle-associated protein in rat hepatocytes |
| Q38074154 | Modulation of immunity by antiangiogenic molecules in cancer |
| Q38226097 | Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. |
| Q92879135 | Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression |
| Q90429149 | Multiparametric analysis of colorectal cancer immune responses |
| Q38165001 | Neuropilin 1: function and therapeutic potential in cancer |
| Q47685069 | Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma |
| Q89741649 | New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer |
| Q38837269 | Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression |
| Q90150429 | Noninvasive Identification of Immune-Related Biomarkers in Hepatocellular Carcinoma |
| Q26769884 | Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential |
| Q49887965 | Novel targeted therapies and immunotherapy for advanced thyroid cancers |
| Q39456860 | Oncolytic Viruses: Exploiting Cancer's Deal with the Devil |
| Q37179971 | PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapy |
| Q99240043 | Perineural Invasion and Postoperative Complications are Independent Predictors of Early Recurrence and Survival Following Curative Resection of Gastric Cancer |
| Q61814599 | Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab |
| Q92434457 | Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 tria |
| Q64094384 | Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma |
| Q90731806 | Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer |
| Q90163744 | Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies |
| Q57118798 | Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF) |
| Q91851580 | Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial |
| Q38728953 | Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma |
| Q92129582 | Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? |
| Q90220063 | Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy |
| Q91297827 | Regulatory T cells in cancer immunosuppression - implications for anticancer therapy |
| Q38809637 | Regulatory T cells in oral squamous cell carcinoma |
| Q42102497 | Regulatory T-cell heterogeneity and the cancer immune response |
| Q38809776 | Reversing T-cell Dysfunction and Exhaustion in Cancer |
| Q38188582 | Review of angiogenesis in hepatocellular carcinoma |
| Q28080176 | Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer |
| Q55288740 | Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors. |
| Q92405303 | T Cell Dysfunction in Cancer Immunity and Immunotherapy |
| Q52596337 | T Cell Dysfunction in Cancer. |
| Q37277182 | TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies |
| Q38985243 | TREG Cells in Cancer: Beyond Classical Immunological Control |
| Q39441315 | Targeted Therapy and Immunosuppression in the Tumor Microenvironment |
| Q38821915 | Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma |
| Q40485583 | Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis |
| Q55008337 | Targeting VEGF/VEGFR to Modulate Antitumor Immunity. |
| Q57476222 | Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 T cells in the tumor microenvironment |
| Q92408693 | Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies |
| Q38077405 | Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. |
| Q92024962 | Targeting innate sensing in the tumor microenvironment to improve immunotherapy |
| Q27026329 | Targeting the tumor vasculature to enhance T cell activity |
| Q28553277 | The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective |
| Q90643245 | The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients |
| Q88549073 | The Role of the Gut Microbiome in Colorectal Cancer |
| Q39034031 | The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia |
| Q92642235 | The Tumor Microenvironment in Colorectal Cancer Therapy |
| Q91963436 | The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis |
| Q92367121 | The double edge sword of fibrosis in cancer |
| Q34994967 | The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. |
| Q38510263 | The functional and prognostic implications of regulatory T cells in colorectal carcinoma |
| Q36887861 | The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. |
| Q41499942 | The role and significance of VEGFR2+ regulatory T cells in tumor immunity |
| Q47134647 | Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies |
| Q64071046 | Therapy with CD4CD25 T regulatory cells - should we be afraid of cancer? |
| Q93139113 | Towards individualized therapy for metastatic renal cell carcinoma |
| Q55518010 | Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. |
| Q37057942 | Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer |
| Q64066769 | Umbilical cord blood‑derived Helios‑positive regulatory T cells promote angiogenesis in acute lymphoblastic leukemia in mice via CCL22 and the VEGFA‑VEGFR2 pathway |
| Q92147400 | Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response |
| Q37618011 | VEGF blockade enhances the antitumor effect of BRAFV600E inhibition. |
| Q35064894 | VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors |
| Q42969280 | VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer |
| Q41265675 | Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases |
| Q36847357 | Vascular normalization as an emerging strategy to enhance cancer immunotherapy |
| Q38130686 | Vascular permeability and drug delivery in cancers |
| Q39024164 | Vessel pruning or healing: endothelial metabolism as a novel target? |
| Q43544239 | siRNA-participated chemotherapy: an efficient and specific therapeutic against gastric cancer |
Search more.